📊 CTTH Key Takeaways
Is Ctt Pharmaceutical Holdings, Inc.. (CTTH) a Good Investment?
CTT Pharmaceutical Holdings is an effectively dormant company with no revenue generation, persistent operating losses, and severely depleted cash reserves ($32.1K). The company is burning cash at an unsustainable rate (-$84.3K operating cash flow) while showing no path to profitability or operational recovery. The dramatic mismatch between its sector classification (Gold and Silver Ores) and company name (Pharmaceutical) suggests potential shell company status or significant business discontinuation.
Fundamentals are extremely weak: the company shows no reported revenue, persistent operating and net losses, and negative operating/free cash flow. While liabilities are low and the current ratio appears healthy, the balance sheet is small, cash is limited, and the 2015-09-30 data is too stale to support any constructive fundamental view.
Why Buy Ctt Pharmaceutical Holdings, Inc.. Stock? CTTH Key Strengths
- Strong current ratio of 3.70x indicates short-term liquidity position relative to liabilities
- Zero long-term debt eliminates financial leverage risk
- Positive stockholders equity of $738.1K provides theoretical going concern basis
- Low reported leverage with essentially no long-term debt
- Positive stockholders' equity of $738.08K exceeds total liabilities
- Current and quick ratios of 3.70x indicate near-term obligations were covered at the reporting date
CTTH Stock Risks: Ctt Pharmaceutical Holdings, Inc.. Investment Risks
- Complete absence of revenue with no indication of business operations
- Negative operating cash flow of -$84.3K combined with minimal cash reserves of $32.1K indicates imminent liquidity crisis
- Severely negative ROE (-141.1%) and ROA (-113.0%) demonstrate destruction of shareholder capital
- Stale financial data from September 2015 (10+ years old) prevents current viability assessment
- Sector-company name mismatch suggests dormant or shell company status with no active business
- No insider activity in past 90 days suggests abandonment of the company
- No reported revenue base, making the business model and growth quality highly questionable
- Net loss of $1.04M and ROE of -141.1% indicate severe profitability weakness
- Only $32.12K of cash alongside negative operating cash flow raises funding and going-concern risk
Key Metrics to Watch
- Operating cash flow trend and cash depletion rate
- Any revenue generation or new business operations
- Updated financial filings and company status with SEC
- Sustainable revenue generation and gross profit emergence
- Operating cash flow and ending cash balance
Ctt Pharmaceutical Holdings, Inc.. (CTTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.70x current ratio provides a solid financial cushion.
CTTH Profit Margin, ROE & Profitability Analysis
CTTH vs Market Sector: How Ctt Pharmaceutical Holdings, Inc.. Compares
How Ctt Pharmaceutical Holdings, Inc.. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ctt Pharmaceutical Holdings, Inc.. Stock Overvalued? CTTH Valuation Analysis 2026
Based on fundamental analysis, Ctt Pharmaceutical Holdings, Inc.. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ctt Pharmaceutical Holdings, Inc.. Balance Sheet: CTTH Debt, Cash & Liquidity
CTTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ctt Pharmaceutical Holdings, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
CTTH Revenue Growth, EPS Growth & YoY Performance
Ctt Pharmaceutical Holdings, Inc.. Dividends, Buybacks & Capital Allocation
CTTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ctt Pharmaceutical Holdings, Inc.. (CIK: 0001035422)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTTH
What is the AI rating for CTTH?
Ctt Pharmaceutical Holdings, Inc.. (CTTH) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTTH's key strengths?
Claude: Strong current ratio of 3.70x indicates short-term liquidity position relative to liabilities. Zero long-term debt eliminates financial leverage risk. ChatGPT: Low reported leverage with essentially no long-term debt. Positive stockholders' equity of $738.08K exceeds total liabilities.
What are the risks of investing in CTTH?
Claude: Complete absence of revenue with no indication of business operations. Negative operating cash flow of -$84.3K combined with minimal cash reserves of $32.1K indicates imminent liquidity crisis. ChatGPT: No reported revenue base, making the business model and growth quality highly questionable. Net loss of $1.04M and ROE of -141.1% indicate severe profitability weakness.
What is CTTH's revenue and growth?
Ctt Pharmaceutical Holdings, Inc.. reported revenue of N/A.
Does CTTH pay dividends?
Ctt Pharmaceutical Holdings, Inc.. does not currently pay dividends.
Where can I find CTTH SEC filings?
Official SEC filings for Ctt Pharmaceutical Holdings, Inc.. (CIK: 0001035422) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTTH's EPS?
Ctt Pharmaceutical Holdings, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CTTH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ctt Pharmaceutical Holdings, Inc.. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CTTH stock overvalued or undervalued?
Valuation metrics for CTTH: ROE of -141.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CTTH stock in 2026?
Our dual AI analysis gives Ctt Pharmaceutical Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTTH's free cash flow?
Ctt Pharmaceutical Holdings, Inc..'s operating cash flow is $-84.3K, with capital expenditures of N/A.
How does CTTH compare to other Market stocks?
Vs Default sector averages: Net margin N/A (avg: 12%), ROE -141.1% (avg: 15%), current ratio 3.70 (avg: 1.8).